FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer By Ogkologos - April 8, 2026 285 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection MOST POPULAR WHO’s plans to create a ‘cervical cancer-free future’ April 19, 2021 Zenocutuzumab Shows Efficacy in Patients with Advanced NRG1 Fusion-positive Cancers February 19, 2025 Temporary Interruption of Endocrine Therapy for Pregnancy, Including Use of Fertility... July 20, 2026 FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs... October 16, 2025 Load more HOT NEWS Man Who Lost Wife to Breast Cancer Wants to Donate Her... ESMO 2024 Press Conference EMA Recommends Extension of Therapeutic Indications for Durvalumab Cancer and Climate Change: The Health Threats of Unnatural Disasters
